July 15, 2019 - 08:07 pm
0 Comments
Introduction
OBR and MDoutlook are pleased to share excerpts from the most recent MDoutlook OncoPolls™ following this year’s ASCO annual meeting in Chicago. This final report (from series of three releases with MDoutlook over the past week) highlights the three (3) oral presentations from Tuesday morning ASCO presentations concerning chronic lymphocytic leukemia (CLL). These presentations discussed the first-line use of Venetoclax + Obinutuzumab, the use of Acalabrutinib + Obinutuzumab in both the first-line and relapsed/refractory settings, and the CAR-T product Lisocabtagene maraleucel.
This research is based on separate, identical surveys conducted with US and EU5-based oncologists who treat CLL. The full complimentary report is available through MDoutlook.
OncoPoll™ Methodology
Abstract #7502: Venetoclax plus Obinutuzumab as a 1st line treatment for CLL
Key Conclusions about Abstract #7502 (Venetoclax + Obinutuzumab in first-line CLL)
Abstract #7500: Acalabrutinib plus Obinutuzumab for 1st line CLL and r/r CLL
Key Conclusions about Abstract #7500 (Acalabrutinib + Obinutuzumab in untreated and r/r CLL)
Abstract #7501: Lisocabtagene Maraleucel (Liso-Cel) in r/r CLL
Key Conclusions about Abstract #7501 (Liso Cel in r/r CLL)
Expected Integration of New ASCO Data into Clinical Practices
Key Conclusions about Integration of New ASCO Data into Clinical Practice
Overall Conclusions: Immediate Impact of 2019 ASCO Presentations on the Clinical Practice for CLL
For a more detailed analysis report, please click here to visit MDoutlook or click here to obtain this report.
Submitted by Robert Stephan, SVP, Research & Operations and Jan Heybroek, President, MDoutlook.
July 11, 2019 - 02:07 pm
0 Comments
Introduction
OBR and MDoutlook are pleased to share more excerpts from the most recent MDoutlook OncoPolls™ following this year’s ASCO annual meeting in Chicago. This report highlights four (4) oral presentations concerning new targeted agents being developed against recognized driver mutations in metastatic non-small cell lung cancer (mNSCLC). These agents are: Capmatinib and Tepotinib (both targeting MET with exon 14 mutations), TAK-788 (targets specific EGFR mutations with exon 20 insertions), and BLU-667 (RET inhibitor).
This research is based on separate, identical surveys conducted with US and EU5-based treaters of mNSCLC. The full complimentary report is available through MDoutlook per details below.
OncoPoll™ Methodology
Current Awareness and Evaluation of New Targeted Agents in mNSCLC
Key Conclusions around New Targeted Agents for mNSCLC
Comparison of New Targeted Agents for mNSCLC
Key Conclusions about Comparison of New Targeted Agents for mNSCLC
Overall Conclusions: Impact of 2019 ASCO Annual Meeting on Clinical Practice for mNSCLC with Driver Mutations
For a more detailed analysis report, please click here to visit MDoutlook or click here to view this report.
Submitted by: Robert Stephan, SVP, Research & Operations and Jan Heybroek, President MDoutlook.
July 08, 2019 - 03:07 pm
0 Comments
Introduction
OBR and MD Outlook are pleased to share excerpts from the most recent MDoutlook’s OncoPolls™ from his year’s ASCO annual meeting in Chicago. This report highlights three presentations concerning the use of 2nd generation anti-androgens (2nd gen AAs) in the treatment of “early advanced” prostate cancer: non-metastatic, castration resistant prostate cancer (nmCRPC) and metastatic, hormone sensitive prostate cancer (mHSPC).
This research is based on separate, identical surveys conducted with US and EU5-based treaters of prostate cancer. The full complimentary report is available through MDoutlook per details below.
OncoPoll™ Methodology
Abstract #5000: Darolutamide in nmCRPC
Key Conclusions about Abstract #5000 (Darolutamide in nmCRPC)
Abstracts #LBA2 & #5006:
Enzalutamide & Apalutamide in mHSPC
Key Conclusions about Abstracts #LBA2 & #5006 (Enzalutamide and Apalutamide in mHSPC)
Overall Conclusions: Immediate Impact of 2019 ASCO Presentations on the Clinical Practice for mHSPC and nmCRPC
For a more detailed analysis report, personalized to suit your informational needs, please click here to visit MDoutlook or click here to view this report.
Submitted by Robert Stephan, SVP, Research & Operations and Jan Heybroek, President MDoutlook.